These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17882407)

  • 21. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
    Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 23. Prescription-event monitoring--recent progress and future horizons.
    Mann RD
    Br J Clin Pharmacol; 1998 Sep; 46(3):195-201. PubMed ID: 9764958
    [No Abstract]   [Full Text] [Related]  

  • 24. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reporting of adverse drug reactions by nurses.
    Morrison-Griffiths S; Walley TJ; Park BK; Breckenridge AM; Pirmohamed M
    Lancet; 2003 Apr; 361(9366):1347-8. PubMed ID: 12711472
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wonder vigilance.
    Edwards IR
    Drug Saf; 2010 Feb; 33(2):83-6. PubMed ID: 20088622
    [No Abstract]   [Full Text] [Related]  

  • 27. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spontaneous reporting of post-market safety signals: what evidence should support regulatory action?
    Dhodapkar MM; Ross JS; Ramachandran R
    BMJ; 2022 Oct; 379():o2409. PubMed ID: 36198410
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dealing with adverse drug reactions in dentistry. Procedures on encountering adverse drug reactions and goal of the Swiss Pharmacovigilance system].
    Egger SS; Krähenbühl S; Schlienger RG
    Schweiz Monatsschr Zahnmed; 2005; 115(12):1209-18. PubMed ID: 16408825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Encouraging spontaneous reporting of adverse effects.
    Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 35. [Thinking on risk assessment and risk management of post-marketing Chinese medicine].
    Yu X; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):262-4. PubMed ID: 22737865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse reactions: know the risks.
    Shepherd M
    Nurs Times; 2011 Apr 5-11; 107(13):20. PubMed ID: 21678719
    [No Abstract]   [Full Text] [Related]  

  • 37. Adverse drug reaction reporting systems: the United Kingdom and the United States.
    Scott HD; Thacher A; Rosenbaum SE; Waters WJ; Green M
    R I Med J (1976); 1988 May; 71(5):179-84. PubMed ID: 3387803
    [No Abstract]   [Full Text] [Related]  

  • 38. Challenges in collecting, accessing and evaluating post market surveillance AERS in patients receiving dietary supplements.
    Kingston R
    Thromb Res; 2005; 117(1-2):137-44; discussion 145-51. PubMed ID: 16139875
    [No Abstract]   [Full Text] [Related]  

  • 39. The Japanese Postmarketing Adverse Event Relief System: A Confluence of Regulatory Science, the Legal System, and Clinical Pharmacology.
    Tominaga T; Miyazaki S; Oniyama Y; Weber AD; Kondo T
    Clin Pharmacol Ther; 2017 Aug; 102(2):277-282. PubMed ID: 27737512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.